{"id":"comparator-rosiglitazone","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Weight gain"},{"rate":"5-15","effect":"Fluid retention / edema"},{"rate":"variable","effect":"Hypoglycemia (when combined with other agents)"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL121","moleculeType":"Small molecule","molecularWeight":"357.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to PPAR-γ in adipose tissue and muscle, rosiglitazone enhances insulin signaling and glucose uptake, reducing hepatic glucose production and improving peripheral insulin sensitivity. This mechanism addresses the underlying insulin resistance in type 2 diabetes rather than stimulating insulin secretion directly.","oneSentence":"Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:05.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT00879970","phase":"PHASE4","title":"Thiazolidinedione Intervention With Vitamin D Evaluation","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1332},{"nctId":"NCT00541775","phase":"PHASE3","title":"Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus","enrollment":273},{"nctId":"NCT00884533","phase":"PHASE1","title":"QTc Study of Rosi XR in Healthy Volunteers","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2009-06","conditions":"Alzheimer's Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avandia"],"phase":"phase_3","status":"active","brandName":"Comparator: Rosiglitazone","genericName":"Comparator: Rosiglitazone","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosiglitazone is a small molecule that acts as a peroxisome proliferator-activated receptor gamma agonist. It is used to treat conditions such as Type 2 Diabetes Mellitus and Cardiovascular Diseases, among others, as a comparator in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}